Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis
Authors
Keywords
-
Journal
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
Volume 21, Issue 3, Pages 175-184
Publisher
Informa UK Limited
Online
2014-06-11
DOI
10.3109/13506129.2014.927759
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
- (2012) Laura Obici et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition
- (2012) Nelson Ferreira et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
- (2012) Vincenzo Pizza et al. CNS & Neurological Disorders-Drug Targets
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
- (2012) Charles A. Dinarello et al. NATURE REVIEWS DRUG DISCOVERY
- Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: “In Vivo” Evidence from FAP Mice Models
- (2012) Nelson Ferreira et al. PLoS One
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
- (2012) C. E. Bulawa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A clinical perspective of IL-1β as the gatekeeper of inflammation
- (2011) Charles A. Dinarello EUROPEAN JOURNAL OF IMMUNOLOGY
- Chronic inhibition of endoplasmic reticulum stress and inflammation prevents ischaemia-induced vascular pathology in type II diabetic mice
- (2011) Ali Amin et al. JOURNAL OF PATHOLOGY
- Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice
- (2010) Zhen-Qian Wu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models
- (2010) Isabel Cardoso et al. Journal of Translational Medicine
- IL-1 pathways in inflammation and human diseases
- (2010) Cem Gabay et al. Nature Reviews Rheumatology
- The Unfolded Protein Response Is Activated in Pretangle Neurons in Alzheimer's Disease Hippocampus
- (2009) Jeroen J.M. Hoozemans et al. AMERICAN JOURNAL OF PATHOLOGY
- IL-1β receptor blockade protects islets against pro-inflammatory cytokine induced necrosis and apoptosis
- (2009) Alice Schwarznau et al. JOURNAL OF CELLULAR PHYSIOLOGY
- IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
- (2009) J. A. Ehses et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy
- (2008) Bárbara Macedo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Anakinra in Experimental Acute Myocardial Infarction—Does Dosage or Duration of Treatment Matter?
- (2008) Fadi N. Salloum et al. CARDIOVASCULAR DRUGS AND THERAPY
- Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction
- (2008) Antonio Abbate et al. CIRCULATION
- The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems
- (2008) Sofia Duque Santos et al. NEUROBIOLOGY OF AGING
- Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury
- (2008) Krisztina Rusai et al. TRANSPLANT INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started